A carregar...
Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
Lenalidomide is an oral immunomodulatory agent approved in relapsed multiple myeloma with dexamethasone, for transfusion-dependent anemia in myelodysplastic syndrome associated with deletion 5q, and in relapsed/progressive mantle cell lymphoma following bortezomib. In recent clinical trials, lenalid...
Na minha lista:
| Publicado no: | J Adv Pract Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Harborside Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4457182/ https://ncbi.nlm.nih.gov/pubmed/26110071 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|